Dr. Lin Sun-Hoffman, President Dr. Sun-Hoffman is a licensed patent attorney and advises on issues related to intellectual property and technology transfer matters. She also consults on biotechnology and pharmaceutical business-related matters. She helps businesses expand into China through providing strategic and practical advice on issues as diverse as government relations, research and/or business partnerships between Chinese and American companies, intellectual property protection and drug regulatory matters. She previously worked for Life Technologies/ABI, BIO, Celera Genomics, US Patent and Trademark Office and National Institutes of Health. She is the former president of Chinese Biopharmaceutical Association based in Washington DC, currently serves on board of US China Green Energy Council, a member of Bayhelix. Dr. Sun-Hoffman has a PhD in Biochemistry/Cell and Molecular Biology.
Dr. Julie Yang, Public Relations Julie serves as Director, Intellectual Property, at FibroGen, Inc. Julie has 20 plus years of experience in the biotech and pharmaceutical industry, previously in research and management, and over 10 years in IP management. Julie joined FibroGen from Limerick BioPharma, where she was is in charge of Limerick BioPharma’s intellectual property and manages company’s contracts as Senior Director of Intellectual Property. Prior to joining Limerick, Julie was responsible for Genelabs’ entire patent and trademark portfolios. Julie is very active in her community. She has volunteered in CBA for over 8 years. In addition, she also serves on the board of Leading Women in Technology.
Ms. Katherine Wang, Treasurer Katherine Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University (Syracuse, NY). She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later discovered that her real interest is in clinical data analysis. Currently, she is a clinical SAS programmer at Gilead Sciences, doing data analysis in clinical trials: Phase 1 to 4. Prior to Gilead, she worked as certified advanced SAS programmer in Clinovo. Clinovo is a Bio-IT company focusing on meeting the needs of data management of Bio-Pharmaceutical and medical device industries. Katherine has been a volunteer of CBA in past two year as treasurer. Her diligent work and enthusiasm have been well recognized. She grew up in Wuhan, China and enjoys reading, writing, walking in nature and Scottish Country Dancing.
Mr. Frank Lin, Taiwan Liaison Mr. Frank Lin is the Regional Sales Marketing Director at Specialdeals.com, a VC funded startup a deal-of-the-day website that features discounted gift certificates usable at local or national companies. Frank Lin is the Regional Marketing Director in US and General Manager in Asia Pacific at Matchbin, Inc, a Web 2.0 Content Management System (CMS) provider for newspaper/radio station/magazine industry. Prior to that, Mr. Lin was a Sales Operation / Marketing Specialist at VeriSilicon, a Fabless Semiconductor company. Mr. Lin now is the Marketing Manager at GBC (www.gbc.com.tw). Mr. Lin received his B.A. degree in Electrical and Computer Engineering from Purdue University and an MBA from Santa Clara University.
Mr. Andrew Teng, Taiwan Liaison Currently acting as C.S.O. at Sunwell Scientific Inc. Mr. Teng has more than 16 years of general management experience in the fields of semiconductor and Bio Science. His broad background includes P&L, operational, BD, product development, marketing, IP protection and M&A. He was a Managing Director at Ecos Lab Co. Prior to joining Ecos Lab, Mr. Teng held a senior positions with Encepho Pharmaceutical as V.P. of Business Development. Mr. Teng has extensive international experience having had direct responsibility for business development and strategic planning in Greater China. Mr. Teng has a B.S. degree from San Jose State University
Dr. Patrick Yang, Alliance Dr. Patrick Yang currently is working at Portola Pharmaceuticals, Inc. He has been working in bay area for nine years as scientist/staff scientist in various pharmaceutical companies, Millennium Pharmaceuticals, Inc., Nektar Therapeutics Inc. and Sunesis Pharmaceuticals Inc. Dr. Yang graduated from Nanjing University, and obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA. He also has several years’ working experience in analytical field and management in China. Dr. Yang’s research interests include analytical development, method transfer/validation, pre-formulation/formulation, and controlled release of drug. Additionally, he has previously served on CBA board from 2003 to 2005.
Dr. Shih-Chen Chang , Vice President Dr. Shih-Chen Chang joined in Genentech as a senior epidemiologist in September 2011, he works in virology and transplant therapeutic area and supports the company to understand targeted patient population, drug utilization, prepare relevant report for regulatory submission, and design post-marketing studies to monitor safety signals using non-interventional approach through using observational data resource. Before joining in Genentech, he worked at AstraZeneca in Wilmington, Delaware as an associate director in global epidemiology under patient safety unit, where he focused on oncology and bacterial infection therapeutic area. Shih-Chen Chang also did his post-doctorate training at division of cancer epidemiology and genetics in national cancer institute, and obtained his PhD in school of public health, Johns Hopkins University. He has approximately 30 first and co-authored publications in peer-review journal. He also served as the board committee member in the alumni of National Taiwan University in greater Washington D.C. area in 2003-2004 and the board committee member and chair of the Chinese-American Network association in AstraZeneca in 2009-2011.
Dr. Kai Zheng , Membership Dr. Kai Zheng received his Ph.D. from the Department of Pharmaceutical Chemistry at the University of Kansas. After graduation, he joined Genentech Oceanside site and focused on the protein formulation development at early stages. After working at Oceanside for 4 years, he moved to Genentech SSF site and joined the late stage pharmaceutical development department. He is working on Phase III and commercial formulation development now. When he was in Oceanside, he was a member of SABPA (Sino-American Biomedical and Pharmaceutical Professionals Association) and worked as meeting volunteers.
Chan Gao, Secretary